Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Elicio Therapeutics (ELTX) Other Non Operating Income (2020 - 2026)

Elicio Therapeutics filings provide 4 years of Other Non Operating Income readings, the most recent being -$33000.0 for Q3 2023.

  • On a quarterly basis, Other Non Operating Income changed N/A to -$33000.0 in Q3 2023 year-over-year; TTM through Dec 2023 was $567000.0, a 160.0% increase, with the full-year FY2024 number at $151000.0, down 64.8% from a year prior.
  • Other Non Operating Income hit -$33000.0 in Q3 2023 for Elicio Therapeutics, down from $492000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $492000.0 in Q2 2023 to a low of -$7.2 million in Q4 2021.
  • Median Other Non Operating Income over the past 4 years was -$43000.0 (2021), compared with a mean of -$895357.1.
  • Biggest five-year swings in Other Non Operating Income: tumbled 2319.14% in 2021 and later surged 543.24% in 2023.
  • Elicio Therapeutics' Other Non Operating Income stood at $324000.0 in 2020, then tumbled by 2319.14% to -$7.2 million in 2021, then surged by 86.86% to -$945000.0 in 2022, then soared by 96.51% to -$33000.0 in 2023.
  • The last three reported values for Other Non Operating Income were -$33000.0 (Q3 2023), $492000.0 (Q2 2023), and $108000.0 (Q1 2023) per Business Quant data.